AMR SVG Icons location

Betamethasone Sodium Phosphate and Betamethasone AcetateInjectable Suspension, USP


  • “AB” Rated to Celestone® Soluspan®*1
  • Vial closure is not made with natural rubber latex
  • J Code 0702

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Product Info Availability
Strength:

6 mg/mL

Supplied As:

5 mL
Multiple Dose Vial

NDC#: 0517-0720-01
0517-0720-01

6 mg/mL

5 mL
Multiple Dose Vial

1 Limited Availability
  • Shelf Pack 1
  • Availability Limited Availability

Preserved with Benzalkonium Chloride

Wholesaler Numbers

  • ABC/SAP 10009255
  • Cardinal 4299483
  • McKesson 1973130
  • Morris & Dickson 048793

Case Information

  • Unit of Sale NDC 0517-0720-01
  • Order Size Varies
  • Case Size 80
  • Case Per Tier 17 cases
Strength:

6 mg/mL

Supplied As:

5 mL
Multiple Dose Vial

NDC#: 0517-0791-01
0517-0791-01

6 mg/mL

5 mL
Multiple Dose Vial

1 Out of Stock
  • Shelf Pack 1
  • Availability Out of Stock

NOVAPLUS

Wholesaler Numbers

  • ABC 10234088
  • Cardinal 5602792
  • McKesson 1520741
  • Morris & Dickson 893644

Case Information

  • Unit of Sale NDC 0517-0791-01
  • Order Size 1
  • Case Size 80
  • Case Per Tier 102
Strength:

6 mg/mL

Supplied As:

5 mL
Multiple Dose Vial

NDC#: 0517-0799-01
0517-0799-01

6 mg/mL

5 mL
Multiple Dose Vial

1 Available - Short Dated
  • Shelf Pack 1
  • Availability Available - Short Dated

PremierPro Rx

Wholesaler Numbers

  • ABC 10234983
  • Cardinal 5613534
  • McKesson 1525344
  • Morris & Dickson 901611

Case Information

  • Unit of Sale NDC 0517-0799-01
  • Order Size 1
  • Case Size 80
  • Case Per Tier 102

*Celestone® and Soluspan® are registered trademarks of Merck Sharp & Dohme Corp.
1. Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=090747. Updated February 2018. Accessed March 16, 2018.

Contact Us

Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent database, please submit a message request to corpcommunications@americanregent.com.

Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP

For Intramuscular Use. For intra-articular or soft tissue administration. For intralesional administration.

INDICATIONS AND USAGE
When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows:

Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.

Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).

Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.

Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.

Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.

Miscellaneous
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.

Neoplastic Diseases
For palliative management of leukemias and lymphomas.

Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.

Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.

Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.

Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is contraindicated in patients who are hypersensitive to any components of this product. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.

WARNINGS
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension should not be administered intravenously.

Serious Neurologic Adverse Reactions with Epidural Administration: Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids.

General: Rare instances of anaphylactoid/anaphylactic reactions with a possibility of shock have occurred in patients receiving parenteral corticosteroid therapy. Use caution in patients who have a history of allergic reactions to corticosteroids.

Cardio-renal: Therapy with corticosteroids should be used with great caution in these patients.

Endocrine: Corticosteroids can produce reversible hypothalamic pituitary adrenal axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.

Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients.

Infections: General: Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. Fungal Infections: Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control drug reactions. Special Pathogens: Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens. Tuberculosis: The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. Viral Infections: Chickenpox and measles can have a more serious or even fatal course in patients on corticosteroids.

Vaccination: Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted.

Neurologic: Reports of severe medical events have been associated with the intrathecal route of administration.

Ophthalmic: Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections.

PRECAUTIONS

General: The lowest possible dose of corticosteroid should be used to control the condition under treatment. A risk/benefit decision must be made in each individual case as to dose and duration of treatment. Kaposi’s sarcoma has been reported in patients receiving corticosteroid therapy, most often for chronic conditions.

Cardio-renal: Use with caution in patients with congestive heart failure, hypertension, or renal insufficiency.

Endocrine: Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy.

Gastrointestinal: Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. There is an enhanced effect of corticosteroids in patients with cirrhosis.

Intra-Articular and Soft Tissue Administration: Intra-articular injected corticosteroids may be systemically absorbed. Appropriate examination of any joint fluid present is necessary to exclude a septic process. Injection of a steroid into an infected site is to be avoided. Local injection of a steroid into a previously injected joint or into unstable joints is generally not recommended. Intra-articular injection may result in damage to joint tissues.

Musculoskeletal: Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation and inhibition of osteoblast function.

Neuro-psychiatric: Acute myopathy has been observed with the use of high doses of corticosteroids. Psychic derangements may appear or be aggravated by corticosteroids.

Drug Interactions: See Full Prescribing Information.

Pregnancy: Teratogenic Effects: Corticosteroids have been shown to be teratogenic in many species. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

Nursing Mothers: Use caution when corticosteroids are administered to a nursing woman.

Pediatric Patients: In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.

ADVERSE REACTIONS

Allergic Reactions: Anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glucosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic adrenocortical and pituitary unresponsiveness, suppression of growth in pediatric patients. Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.

Gastrointestinal: Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels, hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestines (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intralesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures. Neurologic/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration. Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, rare instances of blindness associated with periocular injections, vision blurred. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.

For additional Safety Information, please see Full Prescribing Information. You are encouraged to report Adverse Drug Events (ADEs) to American Regent Inc. at 1-800-734-9236
or to the FDA by visiting www.fda.gov/MedWatch or calling 1-800-FDA-1088.
REF-0188  07/2019